In December 2024 a publication in the Annals of Surgical Oncology analyzed data from the National Cancer Database, showing that HER2 IHC3+ patients had significantly higher pathologic complete response (pCR) rates after neoadjuvant anti-HER2 therapy compared to HER2 IHC2+/ISH+ cases. The study found 54.3% pCR in the breast and 68.7% in the axilla for IHC3+ patients, compared to 22% and 37% in IHC2+/ISH+ cases, reinforcing HER2 IHC3+ as a key predictor of treatment response.
These findings emphasize the importance of precise stratification in HER2+ breast cancer to optimize treatment strategies.
Read more in Annals of Surgical Oncology: https://lnkd.in/esX9AqNs
